Tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT ‐ MAINTAIN
Obesity · 2025
DOI: 10.1002/oby.70014 ↗At a glance
Journal article in Obesity, 2025. Written by Deborah B Horn and 9 co-authors. Institution: University of Texas Center for Obesity Medicine and Metabolic Performance, Department of Surgery, University of Texas McGovern Medical School, Housto…. Major MEDLINE topics: Obesity, Weight Loss, Anti-Obesity Agents. Cited 3 times so far (Crossref); 42 references. The full text is freely available (open access, CC BY 4.0). Funded by: Eli Lilly and Company.
Abstract (original language)
Objective
SURMOUNT‐MAINTAIN aims to evaluate the efficacy and safety of reducing the tirzepatide dose and/or continuing the maximum tolerated dose (MTD) versus placebo in maintaining body weight (BW) reduction achieved with tirzepatide MTD.
Methods
This Phase 3b, multicenter, randomized, parallel‐arm, double‐blinded, placebo‐controlled, 52‐week clinical trial is in progress comparing treatment with once weekly tirzepatide (5 mg and/or MTD of 15 mg or 10 mg) versus placebo in achieving BW reduction maintenance from the initial 60‐week open‐label weight‐loss period on tirzepatide MTD, in adults with obesity (BMI ≥ 30 kg/m 2 or ≥ 27 kg/m 2 with ≥ 1 obesity‐related comorbidity, excluding type 2 diabetes). The primary endpoint is percent maintenance of BW reduction achieved during the weight‐loss period at Week 112 among those who reached a BW plateau (i.e., < 5% BW change) between Weeks 48 and 60.
Results
Participants are mostly female (65%) with a mean ± SD age of 47 ± 13 years, BW 114 ± 27 kg, BMI 40 ± 8 kg/m 2 , and waist circumference 119 ± 18 cm.
Conclusions
The SURMOUNT‐MAINTAIN trial will evaluate whether reducing or continuing the tirzepatide dose as a long‐term treatment option may help maintain the reduced BW initially achieved with tirzepatide MTD versus switching to placebo. Combined, this study may provide additional evidence to help tailor patient‐centered strategies for maintenance of BW reduction in adults living with obesity. Trial Registration ClinicalTrials.gov identifier: NCT06047548 image
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- University of Texas Center for Obesity Medicine and Metabolic Performance, Department of Surgery, University of Texas McGovern Medical School, Houston, Texas, USA.
- Comprehensive Weight Control Center, Division of Endocrinology, Diabetes & Metabolism, Weill Cornell Medicine, New York, New York, USA.
- University of Toronto and Wharton Weight Management Clinic, Toronto, Ontario, Canada.
- Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky, USA.
- Eli Lilly and Company, Indianapolis, Indiana, USA.
ORCID profiles: Louis J Aronne, Sean Wharton, Harold E Bays, Julia P Dunn
Funding
- Eli Lilly and Company
Cite
APA
Horn, D. B., Aronne, L. J., Wharton, S., Bays, H. E., Gomez-Valderas, E., Arad, A. D., Sharma, P., Dunn, J. P., Senyucel, C., & Lee, C. J. (2025). Tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT ‐ MAINTAIN. Obesity. https://doi.org/10.1002/oby.70014
Vancouver
Horn DB, Aronne LJ, Wharton S, Bays HE, Gomez-Valderas E, Arad AD, et al. Tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT ‐ MAINTAIN. Obesity. 2025. doi:10.1002/oby.70014
BibTeX
@article{Horn2025,
author = {Horn, Deborah B and Aronne, Louis J and Wharton, Sean and Bays, Harold E and Gomez-Valderas, Elisa and Arad, Avigdor D and Sharma, Palash and Dunn, Julia P and Senyucel, Cagri and Lee, Clare J},
title = {Tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT ‐ MAINTAIN},
journal = {Obesity},
year = {2025},
doi = {10.1002/oby.70014}
}
EUVIMED